LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

MRK

119.71

-1.31%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

MRK

119.71

-1.31%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

MRK

119.71

-1.31%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

MRK

119.71

-1.31%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

MRK

119.71

-1.31%↓

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Closed

SectorHealthcare

423.25 -2.48

Buy Sell

Overview

Share price change

24h

Current

Min

416.3

Max

435.55

Key metrics
By Trading Economics
Income	56M -59M
Sales	34M 321M
Profit margin	-18.243
Employees	915
EBITDA	56M -50M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+59.52% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	-661M 9.9B
Previous open	425.73
Previous close	423.25

News Sentiment

By Acuity

14%

86%

18 / 352 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 mar 2026, 18:43 UTC

Major News Events

Fed's Kashkari Says Too Soon To Know Inflation Impact From Middle East Conflict

3 mar 2026, 17:33 UTC

Acquisitions, Mergers, Takeovers

Ziff Davis to Sell Connectivity Division to Accenture for $1.2 Billion -- Update

3 mar 2026, 23:45 UTC

Market Talk

Nikkei May Fall on Continued Concerns About Energy Costs -- Market Talk

3 mar 2026, 23:44 UTC

Market Talk

Major News Events

Gold Rises on Possible Dip-Buying Amid Ongoing Middle East Conflict -- Market Talk

3 mar 2026, 23:25 UTC

Market Talk

Bannerman Energy Likely to Raise Less Equity for Uranium Projects -- Market Talk

3 mar 2026, 23:25 UTC

Market Talk

Global Energy Roundup: Market Talk

3 mar 2026, 22:38 UTC

Major News Events

Iran Conflict Pushes Europe Toward Fresh Energy Crisis -- WSJ

3 mar 2026, 22:16 UTC

Earnings

Berkshire Provides Scant Fourth-Quarter Financials. Investors Need to Do Their Own Calculations. -- Barrons.com

3 mar 2026, 22:09 UTC

Earnings

Century Aluminum Changed Historical Method of Proportionately Consolidating Jamalco Production Assets to a Full Consolidation

3 mar 2026, 22:06 UTC

Earnings

Century Aluminum: Accounting Change for 2023 and 2024 Doesn't Impact Net Income Attributable to Century Stockholders

3 mar 2026, 22:05 UTC

Earnings

Century Aluminum Initially Concluded That an Accounting Change Was Immaterial, SEC Staff Disagreed With Company's Materiality Conclusion

3 mar 2026, 22:03 UTC

Earnings

Century Aluminum to Restate Certain Results in Connection Wtih Accounting Change for Jamalco

3 mar 2026, 21:50 UTC

Market Talk

Major News Events

Tech, Media & Telecom Roundup: Market Talk

3 mar 2026, 21:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

3 mar 2026, 21:45 UTC

Major News Events

The Iran War Puts the Fed's Rate-Cut Timeline in Doubt -- Barrons.com

3 mar 2026, 21:37 UTC

Earnings

EVgo Stock Rises as Earnings Defy EV Slump. The Rest of 2026 Doesn't Look So Rosy. -- Barrons.com

3 mar 2026, 21:26 UTC

Major News Events

Freeport McMoRan Stock Slides as the Mideast Conflict Hits Commodities -- Barrons.com

3 mar 2026, 20:31 UTC

Market Talk

Major News Events

U.S. Natural Gas Gains on Middle East Turmoil, Weather Outlook -- Market Talk

3 mar 2026, 20:04 UTC

Market Talk

Major News Events

Oil Futures Pull Back as Trump Offers Shipping Protection -- Market Talk

3 mar 2026, 19:17 UTC

Market Talk

Major News Events

Gold and Silver Drop as Energy Surges -- Market Talk

3 mar 2026, 18:43 UTC

Earnings

Berkshire CEO Abel Is Fond of Financial Metric Similar to One Criticized by Buffett -- Barrons.com

3 mar 2026, 18:29 UTC

Market Talk

Major News Events

Global Energy Roundup: Market Talk

3 mar 2026, 18:29 UTC

Market Talk

Major News Events

Norsk Hydro Announces Stoppage of Qatar Aluminum Smelter -- Market Talk

3 mar 2026, 18:22 UTC

Major News Events

Fed's Kashkari on March Projections: Had a Lot of Confidence Up Until a Few Days Ago

3 mar 2026, 18:22 UTC

Major News Events

Fed's Kashkari: Too Soon to Know Impact Iran Conflict Will Have on Inflation

3 mar 2026, 18:17 UTC

Market Talk

Major News Events

Strait of Hormuz Standstill Keeps Bid in Oil Futures -- Market Talk

3 mar 2026, 18:14 UTC

Earnings

How Long Can Anthropic Play Defense? -- WSJ

3 mar 2026, 17:41 UTC

Major News Events

Exxon Is Down Since the Iran Conflict. These Energy Stocks Are Bigger Winners. -- Barrons.com

3 mar 2026, 17:36 UTC

Major News Events

Iran Conflict is Starting to Boost Gasoline Prices -- Update

3 mar 2026, 17:28 UTC

Acquisitions, Mergers, Takeovers

Tinicum, Blackstone to Make Decision on Offer By End of Day March 31

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

59.52% upside

12 Months Forecast

Average 694.9 USD 59.52%

High 964 USD

Low 529 USD

Based on 11 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

18 / 352 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.